Neil Senzer
Impact in
- Oncology top 0.5%
- CAR-T cell therapy research
- Cancer Immunotherapy and Biomarkers
- Biotechnology top 0.5%
- Cancer Research and Treatments
Papers in
- Oncology 94
- CAR-T cell therapy research 25
- Cancer Treatment and Pharmacology 23
- Colorectal Cancer Treatments and Studies 13
-
- RNA Interference and Gene Delivery 23
- Co-authors
- John Nemunaitis (106 shared papers)Donald D. Rao (12 shared papers)Casey Cunningham (25 shared papers)John S. Vorhies (2 shared papers)Manuel Hidalgo (2 shared papers)Phillip B. Maples (20 shared papers)Sanjiv S. Agarwala (2 shared papers)Denis Soulières (1 shared paper)
- Journals
- Journal of Clinical Oncology (55 papers)Molecular Therapy (12 papers)Cancer Gene Therapy (10 papers)Molecular Cancer Therapeutics (7 papers)Clinical Cancer Research (6 papers)
- Partner nations
- United StatesCanadaUnited Kingdom
In The Last Decade
Neil Senzer
176 papers receiving 7.6k citations
Neil Senzer's Hit Papers
Peers
Comparison fields: 5 of 138
- Oncology 3.9k
- Biotechnology 793
- Otorhinolaryngology 386
- Cancer Research 1.0k
- Genetics 1.7k
Countries citing papers authored by Neil Senzer
This map shows the geographic impact of Neil Senzer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Neil Senzer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Neil Senzer more than expected).
Fields of papers citing papers by Neil Senzer
This network shows the impact of papers produced by Neil Senzer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Neil Senzer. The network helps show where Neil Senzer may publish in the future.
Co-authors
The 25 scholars most cited alongside Neil Senzer, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 176 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Multicenter Phase II Study of Erlotinib, an Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck Hit paper breakdown → | 2003 | 654 |
| 2 | 2009 | 469 | |
| 3 | 2009 | 459 | |
| 4 | 2006 | 284 | |
| 5 | 2010 | 263 | |
| 6 | 2003 | 261 | |
| 7 | 2008 | 221 | |
| 8 | 2009 | 205 | |
| 9 | 2001 | 201 | |
| 10 | 2019 | 191 | |
| 11 | 2013 | 186 | |
| 12 | 2004 | 166 | |
| 13 | 2004 | 165 | |
| 14 | 2004 | 149 | |
| 15 | 2005 | 143 | |
| 16 | 2008 | 132 | |
| 17 | 2011 | 128 | |
| 18 | 2012 | 118 | |
| 19 | 2009 | 116 | |
| 20 | 2011 | 113 |
About Neil Senzer
Neil Senzer is a scholar working on Oncology, Molecular Biology, Pulmonary and Respiratory Medicine, Genetics and Biotechnology, having authored 176 papers that have together received 7.8k indexed citations. Recurring topics across this work include Cancer Research and Treatments (40 papers), Virus-based gene therapy research (39 papers), CAR-T cell therapy research (25 papers), Cancer Treatment and Pharmacology (23 papers), RNA Interference and Gene Delivery (23 papers), Immunotherapy and Immune Responses (15 papers), Lung Cancer Treatments and Mutations (15 papers) and Colorectal Cancer Treatments and Studies (13 papers). The work is most often cited by research in Oncology (3.9k citations), Biotechnology (793 citations), Otorhinolaryngology (386 citations), Cancer Research (1.0k citations) and Genetics (1.7k citations). Neil Senzer has collaborated with scholars based in United States, Canada and United Kingdom. Frequent co-authors include John Nemunaitis, Donald D. Rao, Casey Cunningham, John S. Vorhies, Manuel Hidalgo, Phillip B. Maples, Sanjiv S. Agarwala, Denis Soulières, Everett E. Vokes and Lillian L. Siu. Their work appears in journals such as Journal of Clinical Oncology, Molecular Therapy, Cancer Gene Therapy, Molecular Cancer Therapeutics and Clinical Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.